Garda

Merck Faces $200 Million Hit from Tariffs as Gardasil Sales Decline

2 days ago

In a challenging turn of events for Merck & Co., the pharmaceutical giant is bracing for an anticipated $200 million financial impact due to new tariffs that are significantly affecting the sales of its cervical cancer vaccine, Gardasil. This downturn in revenue comes as global sales of the vaccine have dropped drastically, placing further pressure on the company’s financial outlook.

Chinese HPV Vaccines Disrupt Merck's Gardasil Success: A Market in Turmoil

3 days ago

In a significant development within the pharmaceutical industry, the increasing availability of affordable Chinese human papillomavirus (HPV) vaccines is casting a shadow over Merck's Gardasil, which has long been considered the gold standard in HPV prevention. The recent entry of these lower-cost alternatives into the market is driving a seismic shift, turning what was once a booming sales trend for Gardasil into a concerning downturn.

Merck Suspends Gardasil Sales in China, Influencing 2025 Financial Projections

3 months ago

In a significant move that has sent ripples through the pharmaceutical industry, Merck & Co. has announced the cessation of sales for its Gardasil vaccine in China. This decision has far-reaching implications for the company's financial outlook for 2025, as China has been a pivotal market for the HPV vaccine.

Barclays Expands Japan Rates Business with Strategic Hire of Ex-Garda Portfolio Manager Takemura

3 months ago

In a significant move aimed at bolstering its operations in the Japanese financial market, Barclays has announced the appointment of ex-Garda portfolio manager, Takemura. This strategic hire comes as the bank seeks to strengthen its presence in the competitive rates business of Japan.

Star Trader from Garda to Manage $1 Billion for Schonfeld Amid Ongoing Legal Disputes

4 months ago

In a significant development within the finance sector, Garda’s renowned star trader is set to take the helm of a substantial $1 billion fund under Schonfeld Strategic Advisors. This announcement comes amidst an ongoing lawsuit involving both parties, raising eyebrows and concerns within the investment community.

Garda Investments Alleges Competitor Schonfeld of Unlawful Poaching of Key Portfolio Manager

5 months ago

In a significant development within the investment management sector, Garda Capital Partners, a Toronto-based investment firm, has publicly accused its competitor Schonfeld Strategic Advisors of unlawfully enticing away a star portfolio manager. This accusation raises questions about ethics and competitive practices in the finance industry as the firms jockey for top talent to manage investments effectively.

Merck Adjusts Sales Forecast Amid Slowing Demand for Gardasil Vaccine in China

6 months ago

In a recent update, Merck & Co. has revised its sales outlook downward, largely attributed to subpar demand for its Gardasil vaccine in the Chinese market. The pharmaceutical giant is now bracing for a potential decline in sales as the uptake of their human papillomavirus (HPV) vaccine fails to meet projections.

BC Partners to Divest Majority Stake in Canada’s GardaWorld in $5.2 Billion Deal

6 months ago

In a significant development within the private equity landscape, BC Partners has announced its agreement to sell a majority stake in GardaWorld Security Corporation, a prominent Canadian security company, for a substantial $5.2 billion. This major financial transaction marks a decisive move for BC Partners as it seeks to capitalize on the rapid growth of GardaWorld in the security services industry.